上海市通力律师事务所 关于北京百普赛斯生物科技股份有限公司 2025 年第四次临时股东会的法律意见书 致:北京百普赛斯生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受北京百普赛斯生物科技股份有限公司 (以下简称"公司")的委托,指派本所黄雅程律师、张幸律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规 和规范性文件(以下统称"法律法规")及《北京百普赛斯生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第四次临时股东会(以下简称"本次股东会") 相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有签 署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有效 的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 ...

Core Viewpoint - The company Baipusais has shown significant financial growth, with a notable increase in revenue and net profit year-on-year, indicating strong operational performance and investor interest [2][3]. Financing and Trading Activity - On November 11, Baipusais had a trading volume of 58.50 million yuan, with a net financing purchase of 1.73 million yuan after a financing buy of 4.49 million yuan and a repayment of 2.75 million yuan [1]. - The total margin balance for Baipusais reached 113 million yuan, with the financing balance accounting for 1.09% of the circulating market value, indicating a high level of financing activity compared to the past year [1]. - In terms of short selling, Baipusais had no shares repaid on November 11, with 1,200 shares sold short, amounting to 73,500 yuan, and a short balance of 6,800 shares valued at 416,700 yuan, also reflecting a high level of activity [1]. Financial Performance - For the period from January to September 2025, Baipusais reported a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, which is a 58.61% increase compared to the previous year [2]. - Cumulatively, Baipusais has distributed 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, Baipusais had 10,600 shareholders, a decrease of 9.75% from the previous period, while the average number of circulating shares per shareholder increased by 54.93% to 11,947 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the second-largest, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3].

Investment Rating - Maintain "Outperform" rating with a target price of 74.78 RMB, reflecting a 10% upside from the current price [4][11]. Core Insights - The innovative drug industry is rebounding, leading to strong company performance with a revenue increase of 32.26% year-on-year in the first three quarters of 2025, reaching 613 million RMB, and a net profit attributable to shareholders of 132 million RMB, up 58.61% [4][11]. - The company has seen rapid quarterly revenue growth, with Q3 2025 revenue at 226 million RMB, representing a year-on-year increase of 37.50% and a quarter-on-quarter increase of 12.32% [12]. - Increased R&D investment has diversified the product range, with nearly 60 GMP-grade products developed for CGT drug CMC, commercialization, and clinical research [13]. Financial Summary - Total revenue projections for 2023A to 2027E are as follows: 544 million RMB (2023A), 645 million RMB (2024A), 840 million RMB (2025E), 1,074 million RMB (2026E), and 1,366 million RMB (2027E), with growth rates of 14.6%, 18.6%, 30.2%, 27.8%, and 27.2% respectively [3]. - Net profit attributable to shareholders is projected to grow from 154 million RMB in 2023A to 354 million RMB in 2027E, with a significant increase of 53.9% in 2025E [3]. - The company’s EPS is forecasted to be 0.92 RMB (2023A), 0.74 RMB (2024A), 1.14 RMB (2025E), 1.53 RMB (2026E), and 2.11 RMB (2027E) [3][4]. R&D and Product Development - The company has developed a series of recombinant proteins and antibodies for CAR-T product development, enhancing its capabilities in the CGT field [12][13]. - In the ADC field, the company offers a range of high-quality products, including target proteins and enzymes for linker cleavage, which are essential for ADC PK research [13].

Core Insights - The company reported strong financial performance for Q1-Q3 2025, with revenue of 613 million and a year-on-year growth of 32.26%, and a net profit of 132 million, up 58.61% year-on-year [1] - The company plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its international presence and expand its global financing and acquisition channels [3] - The company focuses on recombinant proteins and GMP-grade raw materials, which are crucial for the development and production of CGT innovative drugs [4] Financial Performance - For Q3 2025, the company achieved revenue of 226 million, a year-on-year increase of 37.50% and a quarter-on-quarter increase of 12.32% [1] - The net profit for Q3 2025 was 48.62 million, reflecting an 81.46% year-on-year growth and a 12.49% quarter-on-quarter growth [1] - The company’s operating expenses have been effectively managed, with a decrease in sales, management, and R&D expense ratios compared to the previous year [2] Strategic Initiatives - The company is enhancing its operational efficiency through cost control and improved management practices, leading to a reduction in expense ratios across various categories [2] - The establishment of overseas subsidiaries and logistics centers is part of the strategy to deepen international operations and ensure comprehensive market coverage [3] - The company aims to strengthen its global supply chain capabilities by building overseas production bases and increasing R&D investments [3] Market Outlook - Revenue forecasts for 2025 and 2026 have been revised upwards to 845 million and 1.041 billion, respectively, with net profits expected to reach 208 million and 233 million [5] - The company anticipates significant revenue growth, projecting 1.288 billion in revenue and 296 million in net profit for 2027 [5]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Insights - The company reported a revenue of 613 million yuan for the first three quarters of 2025, representing a year-on-year growth of 32.26%, and a net profit attributable to the parent company of 132 million yuan, up 58.61% year-on-year [1] - The company plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its international strategy and expand its global financing and acquisition channels [3] - The core business focuses on recombinant protein products, which are crucial for the development and production of innovative drugs in cell and gene therapy [4] Financial Performance - For Q3 2025, the company achieved a revenue of 226 million yuan, a year-on-year increase of 37.50%, and a net profit of 48.62 million yuan, up 81.46% year-on-year [1] - The sales expense ratio decreased to 27.54% in Q3 2025, down 2.57 percentage points year-on-year, indicating improved cost management [2] - The company expects revenues for 2025 and 2026 to be adjusted to 845 million yuan and 1.041 billion yuan, respectively, with net profits projected at 208 million yuan and 233 million yuan [5] Strategic Initiatives - The company is enhancing its overseas presence by establishing new subsidiaries and logistics centers to cover global markets comprehensively [3] - It aims to increase R&D investments and strengthen its international team to drive technological innovation [3] - The company has successfully developed nearly 60 high-quality GMP-grade products, which are essential for large-scale production and clinical research in CGT drugs [4]

北京百普赛斯生物科技股份有限公司 关于召开 2025 年第四次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于召开 2025 年第 四次临时股东会的通知》（公告编号：2025-072），公司将于 2025 年 11 月 13 日 14:30 召开 2025 年第四次临时股东会。本次股东会将采取现场投票和网络 投票相结合的方式召开，根据相关规定，现将有关事项再次提示如下： 一、召开会议的基本情况 证券代码：301080 证券简称：百普赛斯 公告编号：2025-074 1、股东会届次：2025 年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《公司章程》的有关规定。 4、会议时 ...

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].

Core Insights - The stock of Beijing Baipusi Biotechnology Co., Ltd. (百普赛斯) experienced a slight increase of 0.41% on November 6, with a trading volume of 70.91 million yuan [1] - The company reported a financing buy amount of 2.68 million yuan and a financing repayment of 3.83 million yuan on the same day, resulting in a net financing buy of -1.15 million yuan [1] - As of November 6, the total margin balance for Baipusi was 115 million yuan, indicating a high level of financing activity [1] Financing Overview - On November 6, Baipusi had a financing buy of 2.68 million yuan, with a current financing balance of 114 million yuan, which represents 1.13% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of leverage [1] - In terms of securities lending, Baipusi repaid 900 shares on November 6, with no shares sold, resulting in a lending balance of 34.54 thousand yuan, which is below the 40th percentile of the past year [1] Business Performance - As of September 30, Baipusi had 10,600 shareholders, a decrease of 9.75% from the previous period, while the average number of circulating shares per person increased by 54.93% to 11,947 shares [2] - For the period from January to September 2025, Baipusi achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [2] Dividend and Shareholding Structure - Since its A-share listing, Baipusi has distributed a total of 432 million yuan in dividends, with 312 million yuan distributed over the past three years [3] - As of September 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3] - Other notable shareholders include China Europe Medical Health Mixed A and China Europe Medical Innovation Stock A, with significant increases in their holdings [3]

Core Viewpoint - The stock of Beijing Baipusi Biotechnology Co., Ltd. has experienced fluctuations, with a year-to-date increase of 90.35% but a recent decline of 8.20% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Baipusi achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26% [2] - The net profit attributable to shareholders for the same period was 132 million yuan, showing a year-on-year increase of 58.61% [2] Shareholder Information - As of September 30, 2025, the number of Baipusi shareholders decreased by 9.75% to 10,600 [2] - The average number of circulating shares per shareholder increased by 54.93% to 11,947 shares [2] Dividend Distribution - Since its A-share listing, Baipusi has distributed a total of 432 million yuan in dividends, with 312 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3] - The top ten circulating shareholders include several funds, with notable increases in holdings from institutions like China Europe Medical Health Mixed A and China Europe Medical Innovation Stock A [3]

Core Viewpoint - The company reported Q3 2025 revenue of 226 million yuan (+37.5% YoY) and a net profit attributable to shareholders of 48.62 million yuan (+81.5% YoY), continuing a high growth trend in performance [1] - The gross margin for Q3 2025 increased to 93.1%, with stable expense growth, indicating significant profit elasticity due to revenue realization [1] - The company plans to list in Hong Kong, which is expected to enhance its international strategy, expand overseas business, and improve overall competitiveness [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 613 million yuan (+32.3% YoY) and a net profit attributable to shareholders of 132 million yuan (+58.6% YoY) [1] - The adjusted net profit for the same period was 133 million yuan (+58.8% YoY) [1] Profit Forecast and Investment Recommendation - Based on the Q3 report, the profit forecasts for 2025-2027 have been revised upwards, with expected net profits of 191 million yuan, 271 million yuan, and 357 million yuan respectively [2] - The target price is set at 86.94 yuan, based on a 54x PE valuation for 2026, maintaining a "buy" rating [2]